Novartis AG (NVSEF)
| Previous close | 103.00 |
| Open | 98.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 98.00 - 98.01 |
| 52-week range | 90.12 - 109.00 |
| Volume | |
| Avg. volume | 8,727 |
| Market cap | 205.33B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.27 |
| EPS (TTM) | 4.40 |
| Earnings date | 18 July 2024 |
| Forward dividend & yield | 3.76 (3.84%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
ZacksNovartis (NVS) Presents Positive Data on Renal Drugs at ERA
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
GlobeNewswireNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN
PR NewswireNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, pro
